GenEditBio Limited announced that it has received tens of millions of USD in a round of funding jointly led by new investor Shengde Pharmaceutical Group and its subsidiary Lumosa Therapeutics Co., Ltd., on April 7, 2024. The transaction involved participation from new investors Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Innovation & Technology Venture Fund, Innovation & Technology Fund Company, Corporate Venture Fund, Hong Kong Science and Technology Parks, Investment Arm
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
172 TWD | 0.00% | -5.23% | +151.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+151.83% | 870M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- 6535 Stock
- News Lumosa Therapeutics Co., Ltd.
- GenEditBio Limited announced that it has received funding from Lumosa Therapeutics Co., Ltd., Qiming Weichuang Venture Capital Management Company Limited, Innovation & Technology Fund Company, Hong Kong Science and Technology Parks, Investment Arm